IDO1 (Indoleamine 2,3-dioxygenase 1) is a monomeric heme-containing dioxygenase that catalyzes the oxidative cleavage of L-Tryptophan. IDO1 shows elevated expression in some human cancers and is thought to play a role in the tumor immuno-editing process which sets up peripheral tolerance to tumor antigens. It has therefore gained interest as a drug target in cancer therapy, but no inhibitor has advanced to a drug so far. The interaction described in this protocol has been used as a positive control to validate fragments from a screening approach to identify new leads for IDO1 inhibitors.

protein – small molecule interaction | fragment screening | MO-P-038